
#JPM19 starts with Eli Lilly's $8B buyout of Loxo Oncology — so who's next?
Eli Lilly $LLY has paid $8 billion to jump the queue and take a leading role in an emerging — though still small — field of oncology.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,700+ biopharma pros reading Endpoints daily — and it's free.